Based in Waikato, the agricultural heartland of New Zealand, we have established state of the art laboratories, research and cultivation facilities.
Our goal is the development of next-generation cannabinoid therapeutics to support patients health outcomes and improve their quality of life.
Phyto-cannabinoids are remarkable compounds which interact with the human and animal endocannabinoid system and by doing so are able to provide improved health and wellbeing outcomes for patients.
Cannasouth will be formulating medicinal cannabinoid therapeutic products of the highest standard. Using the best quality ingredients and manufacturing techniques to create medicines unrivalled regarding cannabinoid purity, quality and efficacy.
Cannasouth Cultivation is our 50/50 Joint venture with Aaron Craig and family interests. Through this JV we have entered an agreement with Vera Cultivation which guarantees Cannasouth a supply of high-quality raw material, produced in our state-of-the-art Waikato greenhouse.
Providing GMP certified medicines that are safe, traceable and effective is at the heart of Cannasouth. “Good Manufacturing Practice” is the globally recognised quality control system used in pharmaceutical product manufacturing.
We believe in using clean, sustainable, and natural growing environments for our cultivars. Giving patients, doctors, and clinicians the confidence of knowing that our cannabinoid medicines originate from a pure, natural source.
Research and Science
Cannasouth conducts drug discovery, pharmacological bioavailability and drug delivery research programs that support the development of advanced cannabinoid medicines, targeting a broad range of health conditions that patients suffer from.
The quality of our cannabinoid medicines will be a reflection of our commitment to offer patients the highest standard of cannabinoid therapeutic compounds. Patients and their quality of life are at the centre of our product development strategy.